Evidence map›Paper›PMID 34503957›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022

Glucagonlike Peptide-1 Receptor Imaging in Individuals with Type 2 Diabetes.

Olof Eriksson, Irina Velikyan, Torsten Haack, Martin Bossart, Iina Laitinen, Philip J Larsen, Jan Erik Berglund, Gunnar Antoni, Lars Johansson, Stefan Pierrou and 2 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06888167 (Experimental, Drug-free, Cross-sectional, Single-centre Study to Assess the Association Between Metabotypes of Dietary), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06888167 narecruitingnot on this mapstarted 2024, after this paper: background citation

Experimental, Drug-free, Cross-sectional, Single-centre Study to Assess the Association Between Metabotypes of Dietary (Poly)Phenols and Beta-cell Mass and Function.

TypeinterventionalSponsorAzienda Ospedaliero-Universitaria di ParmaRan2024 to 2026Enrolled40ConditionsHealthy VolunteerArmsStudy setting
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Radiosynthesis and preclinical evaluation of [EJNMMI radiopharmacy and chemistry · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

Olof ErikssonAntaros Medical AB, Uppsala, Sweden; olof.eriksson@antarosmedical.com michael.wagner@sanofi.com.
Irina VelikyanDepartment of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Torsten HaackR&D Research Platform, Integrated Drug Discovery, Sanofi, Frankfurt, Germany.
Martin BossartR&D Research Platform, Integrated Drug Discovery, Sanofi, Frankfurt, Germany.
Iina LaitinenGlobal Imaging, Sanofi, Frankfurt, Germany.
Philip J LarsenDiabetes Research, Sanofi, Frankfurt, Germany.
Jan Erik BerglundClinical Trial Consultants AB, Uppsala, Sweden; and.
Gunnar AntoniDepartment of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Lars JohanssonAntaros Medical AB, Uppsala, Sweden.
Stefan PierrouAntaros Medical AB, Uppsala, Sweden.
Joachim TillnerTranslational Medicine, Sanofi, Frankfurt, Germany.
Michael WagnerR&D Research Platform, Integrated Drug Discovery, Sanofi, Frankfurt, Germany; olof.eriksson@antarosmedical.com michael.wagner@sanofi.com.
Sanofi (Germany) · DEUppsala University · SEAntaros Medical (Sweden) · SEClinical Research Consultants (United States) · USSanofi (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The glucagonlike peptide-1 receptor (GLP1R) is a gut hormone receptor, intricately linked to regulation of blood glucose homeostasis via several mechanisms. It is an established and emergent drug target in metabolic disease. The PET radioligand

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 ReceptorGallium RadioisotopesHumansPeptidesPositron-Emission TomographyPositron Emission Tomography Computed TomographyReproducibility of ResultsGallium RadioisotopesGlucagon-Like Peptide-1 ReceptorPeptidesexendinGLP1RPETtype 2 diabetesβ-cell mass

Identifiers

PMID34503957
PMCPMC9051593
OpenAlexW3196606673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.